In a regulatory filing, Immunome (IMNM) disclosed that its CEO Clay Siegall bought 137.1K shares of common stock on March 26th in a total transaction size of $999.5K. Shares are up 7.2% at $7.60 in pre-market trading.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement
- Immunome CTO buys $103.6K in common stock
- Immunome’s Promising Pipeline and Strategic Acquisition Drive Buy Rating
- Immunome’s Promising Pipeline and Strategic Advancements Support Buy Rating
- Immunome’s 2024 Financial Results and Pipeline Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue